Recent results of the follow-up of radium-224-treated ankylosing spondylitis patients
In this epidemiological study of the somatic late-effects risk after incorporation of a short-lived alpha-emitter, 1473 ankylosing spondylitis patients treated with repeated intravenous injections of radium 224 were observed. A control group of 1338 ankylosing spondylitis patients not treated with radium 224 or X-rays provided comparative information on causes of death and lesions possibly related to the disease itself or to chemotherapy. 495 patients in the exposure group and 602 patients in the control group died. Causes of death were ascertained in 483 patients in the exposure group and in 528 patients in the control group. Three cases of malignant tumours in the skeleton were observed in the exposure group versus one case in the control group. Diseases of haematopoietic tissue among living and dead patients included bone marrow failure and leukaemias . In the exposure group three of the leukaemias were of the chronic myeloid type and there was only one of the acute lymphoblastic type, whereas no case of chronic myeloid but three cases of lymphoblastic leukaemia were observed in the untreated controls. The incidence of the myeloproliferative diseases is discussed in comparison to other groups of patients treated with higher and lower doses and rates of radium 224.
Bibliographic Reference: Article: Supplement to British Journal of Radiology, BIR-Report Nr. 21, pp. 25-28
Record Number: 199010617 / Last updated on: 1994-12-01
Original language: en
Available languages: en